Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences (Nasdaq: SLDB) granted 6,580 restricted stock units (RSUs) to one newly hired employee under its 2024 Inducement Stock Incentive Plan.

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) granted 6,580 restricted stock units (RSUs) to one newly hired employee under its 2024 Inducement Stock Incentive Plan. The RSUs vest in four equal annual installments over four years, contingent on continued service, and were approved under Nasdaq Listing Rule 5635(c)(4).

Argus Jun 2 session

-8.48% close to close Open Argus

Details

News Market Reaction – SLDB

On Jun 2, the first trading day after this news, SLDB closed 8.48% below the previous close.

Data tracked by StockTitan Argus for the Jun 2 session.

Key Figures

Current price: $7.34 Price vs 52-week high: -17.21% Price vs 52-week low: 139.48% +3 more

Current price

$7.34

As of latest pre-news market context

Price vs 52-week high

-17.21%

Relative to 52-week high of $8.8661

Price vs 52-week low

139.48%

Above 52-week low of $3.065

Market cap

$696,038,714

Pre-news valuation

Inducement RSUs

6,580 RSUs

Grant to one newly hired employee under 2024 Inducement Plan

Vesting schedule

4 equal annual installments

RSUs vest on each anniversary through year four

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Q1 2026 earnings

   24h Move

   -4.4%

   Reported Q1 results, strong cash of $380.7M, and pipeline progress.

2. May 07

   Clinical trial update

   24h Move

   -1.8%

   First participant dosed in Phase 3 IMPACT DUCHENNE trial for SGT-003.

3. May 01

   Inducement RSU grant

   24h Move

   +1.4%

   8,070 RSUs granted to a new hire under inducement plan.

4. Apr 30

   Conference participation

   24h Move

   +3.0%

   Announced 16 presentations at 29th ASGCT covering multiple programs.

5. Apr 28

   Regulatory designation

   24h Move

   -0.7%

   European Commission granted Orphan Drug designation for SGT-003.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement stock incentive plan

3 terms

restricted stock units financial

"announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired employee"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Senior Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity grant did Solid Biosciences (SLDB) announce on June 1, 2026?

Solid Biosciences announced an inducement grant of 6,580 restricted stock units to one newly hired employee. According to the company, the RSUs were issued under the 2024 Inducement Stock Incentive Plan as a material inducement to the employee’s acceptance of employment.

How do the 6,580 RSUs granted by Solid Biosciences (SLDB) vest over time?

The 6,580 RSUs vest in four equal annual installments on each one-year anniversary of the grant date. According to the company, vesting continues until the fourth anniversary, subject to the employee’s continued service with Solid Biosciences on each vesting date.

Under which plan were Solid Biosciences (SLDB) inducement RSUs granted in June 2026?

The inducement RSUs were granted under Solid Biosciences’ 2024 Inducement Stock Incentive Plan. According to the company, the grant was structured as an inducement material to the employee’s acceptance of employment and complies with Nasdaq Listing Rule 5635(c)(4).

How does Nasdaq Listing Rule 5635(c)(4) relate to Solid Biosciences’ June 2026 RSU grant?

Nasdaq Listing Rule 5635(c)(4) allows equity inducement awards to new employees without shareholder approval. According to the company, Solid Biosciences used this rule to grant 6,580 RSUs as a material inducement to one new hire under its 2024 inducement plan.

What service requirement applies to the new Solid Biosciences (SLDB) inducement RSU award?

The RSU award requires the employee’s continued service with Solid Biosciences through each vesting date. According to the company, failure to remain employed through an anniversary date would prevent vesting of the corresponding annual installment of restricted stock units.